Offering rapid automated segmentation of brain structures, the ClearPoint 2.2 software reportedly enhances visualization for a variety of targeted, MRI-guided procedures.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the artificial intelligence (AI)-enabled ClearPoint 2.2 software, which provides automated segmentation of brain structures from magnetic resonance imaging (MRI) scans.
ClearPoint Neuro, the manufacturer of the software, said it provides rapid segmentation that facilitates a variety of targeted, MRI-guided procedures ranging from deep brain stimulation to laser ablation.
The ClearPoint 2.2 software also includes the Maestro Brain Model, which was recently validated in a study published in NeuroImage. In a quantitative reproducibility analysis, researchers found the combination of the shape-constrained deformable brain model and voxel-wise tissue segmentation was superior to manual expert segmentation.
“The ClearPoint system can now offer fast, peri-procedural segmentation of the cortical structures of the brain to identify both targets and safety zones for cell and gene therapy delivery, laser ablation, biopsy and deep brain stimulation,” noted Joe Burnett, the president and CEO of ClearPoint Neuro.
Study: AI Bolsters Sensitivity for Pneumothorax on CXR and Significantly Reduces Reporting Time
October 30th 2024For clinically actionable pneumothorax, an artificial intelligence algorithm demonstrated a 93 percent AUC and a 96 percent specificity rate in a study involving chest X-rays from over 27,000 adults.